J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jafron Biomedical Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Other Long-Term Assets
ÂĄ122.6m
CAGR 3-Years
32%
CAGR 5-Years
44%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Other Long-Term Assets
ÂĄ61.5m
CAGR 3-Years
67%
CAGR 5-Years
116%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Other Long-Term Assets
ÂĄ263.2m
CAGR 3-Years
-3%
CAGR 5-Years
-4%
CAGR 10-Years
31%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Other Long-Term Assets
ÂĄ2.1B
CAGR 3-Years
64%
CAGR 5-Years
30%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Other Long-Term Assets
ÂĄ1.1B
CAGR 3-Years
13%
CAGR 5-Years
6%
CAGR 10-Years
19%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Other Long-Term Assets
ÂĄ541.5m
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.1B CNY
Industry
Health Care

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Intrinsic Value
46.98 CNY
Undervaluation 36%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
122.6m CNY

Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Other Long-Term Assets amounts to 122.6m CNY.

What is Jafron Biomedical Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
44%

Over the last year, the Other Long-Term Assets growth was 30%. The average annual Other Long-Term Assets growth rates for Jafron Biomedical Co Ltd have been 32% over the past three years , 44% over the past five years .

Back to Top